Drugs / HMPL-A83
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05429008 | Jul 2022 → Apr 2025 | cancer | Hutchmed | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-15 | Hutchison Medipharma Limited | HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China hutch-med.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-A83 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05429008 ↗ |
| Modality | Monoclonal antibody | “humanized anti-CD47 monoclonal antibody” NCT05429008 ↗ |
| Route | Intravenous | “0.3 mg/kg IV QW” NCT05429008 ↗ |
| Target | CD47 | “anti-CD47” NCT05429008 ↗ |